Founded on the September 18th, 2017 and headquartered near Düsseldorf, Germany, Priavoid GmbH is a biopharmaceutical company focused on the development of innovative disease-modifying therapies for patients with severe neurological disorders. Priavoid’s pharmaceutical development programs are exclusively based on d-enantiomeric peptides (all-d-peptides).
The most advanced drug in our pipeline is named PRI-002. The orally available clinical stage drug candidate directly eliminates toxic amyloid-beta (Aß) oligomers for the causal treatment of Alzheimer’s disease (AD). Oral administration resulted in significantly improved cognitive read out in three different in vivo models.
The First-in-Human phase I single ascending dose (SAD) clinical trial of PRI-002 was successfully completed recently, demonstrating favorable safety, tolerability and pharmacokinetic profiles. The phase I multiple ascending dose (MAD) clinical trial started on December 12th, 2018.
The orally available drug candidate PRI-003 has accomplished successful PoC in an in vivo disease model of Amyotrophic lateral sclerosis (ALS). Priavoid accelerates this research program towards clinical development.
PRI-004 is our drug candidate for the treatment of neuropathic pain. The program is ready to initiate clinical research.
Priavoid’s development pipeline is targeting additional orphan and non-orphan CNS disorders caused by misfolded peptides, incl. tauopathies, Huntington’s disease (HD), and Parkinson’s disease (PD).